BioHelix Gets $300K Phase I SBIR to Enhance Isothermal Method with ZNA Tech for HIV Assay | GenomeWeb

By Ben Butkus

BioHelix has received a $300,000 Phase I Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to support the development of a low-cost, rapid, quantitative test for HIV-1, according to recently published grant information.

Under the grant, BioHelix will explore the use of zip nucleic acid, or ZNA, technology to enhance the speed and sensitivity of its isothermal amplification method, called helicase-dependent amplification, or HDA.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.